aNRP2-14 / aTyr Pharma - LARVOL DELTA

aTyr Pharma Announces Notice of Allowance for U.S. Patent for Anti-Neuropilin-2 (NRP2) Monoclonal Antibodies (GlobeNewswire) - "aTyr Pharma, Inc...announced that the U.S. Patent and Trademark Office (USPTO) has provided a Notice of Allowance for a patent covering methods for the use of anti-neuropilin-2 (NRP2) antibodies. The patent application No. 16/376,979 titled, 'Compositions and methods comprising anti-NRP2 antibodies,' covers the use of a series of antibodies targeting NRP2 for differentiated therapeutic applications in the areas of cancer and inflammation....A Notice of Allowance is issued after the USPTO makes the determination that a patent should be granted from an application. A patent from the recently allowed application is expected to be issued in the coming months."

Patent • Oncology

aTyr Pharma Presents Poster Demonstrating Functional Selectivity of Second Anti-NRP2 Antibody (GlobeNewswire) - "The poster presents preclinical findings demonstrating in vitro and in vivo proof-of-concept that the anti-Neuropilin-2 (NRP2) antibody, aNRP2-14, is a high affinity, selective blocker of the Semaphorin 3F/NRP2 interaction."

Preclinical • Oncology